<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39433826</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Real-world analysis of safety, tolerability, and adherence to nirmatrelvir-ritonavir (paxlovid) in primary care COVID-19 outpatients.</ArticleTitle><Pagination><StartPage>24750</StartPage><MedlinePgn>24750</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24750</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-75192-9</ELocationID><Abstract><AbstractText>This retrospective cross-sectional study aims to evaluate the safety, tolerability, and adherence of patients prescribed Nirmatrelvir-ritonavir (Paxlovid) in outpatient settings, focusing on its use in managing category 2 COVID-19 patients across three primary healthcare clinics in Selangor, Malaysia. Data were collected from the Paxlovid pharmacy registry and medical records at Klinik Kesihatan Seksyen 7, Klinik Kesihatan Seksyen 19, and Klinik Kesihatan Kelana Jaya between April 1, 2022, and November 30, 2022. This study analysed data from 415 category 2 COVID-19 patients aged ≥ 18 years. The primary and secondary outcomes included the assessment of patient demographics, Paxlovid dosing, current medication, changes in drug regimen, adherence, and adverse drug reactions (ADR). Pharmacists follow-ups were conducted on days 3 and 5 post-medication initiation. The majority (79.5%) of the cohort experienced ADR, predominantly dysgeusia, diarrhoea, body ache, vomiting, and nausea. Despite this, the ADRs were generally well-tolerated, with no severe impacts reported. High adherence was observed, with 96.9% of patients completing the 5-day regimen. The primary reasons for non-adherence included adverse effect intolerability, dosing ambiguity, forgetfulness, concerns about ADR, and perceived health improvement. Notable medications interacting with Paxlovid were simvastatin, amlodipine, and atorvastatin, and 21.7% of 23 concurrent medications were found not to comply with the recommended interventions by the University of Liverpool COVID-19 Drug Interaction database. Paxlovid demonstrates a high level of safety and tolerability in outpatient COVID-19 patients, with optimal adherence observed. This study underscores the vital role of healthcare professionals in managing Paxlovid within primary healthcare and highlights the need for broader research and direct patient involvement to enhance treatment strategies against COVID-19.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zaharuddin</LastName><ForeName>Zahirah</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Tengku Ampuan Rahimah Hospital, Klang, Selangor, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Md Hussin</LastName><ForeName>Nur Sabiha</ForeName><Initials>NS</Initials><Identifier Source="ORCID">0000-0002-0970-8967</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy Practice and Clinical Pharmacy, Faculty of Pharmacy, Universiti Teknologi MARA Selangor Branch, Puncak Alam Campus, Puncak Alam, Selangor, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karuppannan</LastName><ForeName>Mahmathi</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6503-3191</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy Practice and Clinical Pharmacy, Faculty of Pharmacy, Universiti Teknologi MARA Selangor Branch, Puncak Alam Campus, Puncak Alam, Selangor, Malaysia. k_mahmathi@yahoo.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiology Therapeutics Research Group, Faculty of Pharmacy, Universiti Teknologi MARA Selangor Branch, Puncak Alam Campus, Puncak Alam, Selangor, Malaysia. k_mahmathi@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="Y">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="Y">Primary Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="Y">Outpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055118" MajorTopicYN="Y">Medication Adherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008296" MajorTopicYN="N" Type="Geographic">Malaysia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adverse drug reactions</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Paxlovid</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>23</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39433826</ArticleId><ArticleId IdType="pmc">PMC11494129</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-75192-9</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-75192-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Coronavirus (COVID-19) Dashboard &gt; Cases [Dashboard]. 2023, (World Health Organization, 2023) data.who.int.</Citation></Reference><Reference><Citation>Lin, D. Y. et al. Effectiveness of covid-19 vaccines over a 9-month period in North Carolina. N. Engl. J. Med.386(10), 933–941 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8781317</ArticleId><ArticleId IdType="pubmed">35020982</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur, B. et al. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. Sci. Rep.11(1), 8562 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8058064</ArticleId><ArticleId IdType="pubmed">33879826</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N. Engl. J. Med.386(15), 1397–1408 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase, E. Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ375, n2713 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34750163</ArticleId></ArticleIdList></Reference><Reference><Citation>Marzolini, C. et al. Recommendations for the management of drug–drug interactions between the COVID-19 antiviral nirmatrelvir/ritonavir (paxlovid) and comedications. Clin. Pharmacol. Ther.112(6), 1191–1200 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9348462</ArticleId><ArticleId IdType="pubmed">35567754</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Treatment Guidelines (National Institute of Health, 2022).</Citation></Reference><Reference><Citation>Liverpool COVID-19 Interactions. Available from: https://www.covid19-druginteractions.org/.</Citation></Reference><Reference><Citation>Clinical Management of Confirmed Covid-19 Case in Adult and Paediatric (Ministry of Health Malaysia, 2022).</Citation></Reference><Reference><Citation>Chang, C. T. et al. Managing nirmatrelvir/ritonavir during COVID-19: Pharmacists’ experiences from the Perak state of Malaysia. J. Pharm. Policy Pract.15(1), 70 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9589596</ArticleId><ArticleId IdType="pubmed">36274169</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong, C. K. H. et al. Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: A retrospective cohort study. Lancet Infect. Dis.22(12), 1681–1693 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9401976</ArticleId><ArticleId IdType="pubmed">36029795</ArticleId></ArticleIdList></Reference><Reference><Citation>International Drug Monitoring: The Role of National Centres. Report of a WHO Meeting, inWorld Health Organ Tech Rep Ser., 1–25 (World Health Organization, 1972).</Citation><ArticleIdList><ArticleId IdType="pubmed">4625548</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumgartner, P. C. et al. A systematic review of medication adherence thresholds dependent of clinical outcomes. Front. Pharmacol.9, 1290 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6256123</ArticleId><ArticleId IdType="pubmed">30524276</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew, L. S. et al. Effectiveness of nirmatrelvir/ritonavir (paxlovid) in preventing hospitalization among covid-19 patients: A cohort study in perak, Malaysia. Perak Med. J.2, 14–15 (2022).</Citation></Reference><Reference><Citation>Pesko, B. et al. Safety and tolerability of paxlovid (nirmatrelvir/ritonavir) in high-risk patients. Clin. Infect. Dis.75(11), 2049–2050 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35869852</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzitelli, M. et al. Molnupiravir and nirmatrelvir/ritonavir: tolerability, safety, and adherence in a retrospective cohort study. Viruses15(2), 384 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9962206</ArticleId><ArticleId IdType="pubmed">36851598</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng, C. et al. Safety and efficacy of paxlovid against omicron variants of coronavirus disease 2019 in elderly patients. Infect. Dis. Ther.12(2), 649–662 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9875765</ArticleId><ArticleId IdType="pubmed">36696068</ArticleId></ArticleIdList></Reference><Reference><Citation>A glossary of terms for community health care and services for older persons. , in WHO Centre for Health Development Ageing and Health Technical Report (World Health Organization, 2004).</Citation></Reference><Reference><Citation>Norsihimah, W., Rozana, M. &amp; Kalthom, S. Review on covid-19 assessment centre mortality in perak (January–December 2021). Electron. Perak Med. J.2(Supp 02), 14 (2022).</Citation></Reference><Reference><Citation>Guan, W. J. et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur. Respir. J.55(5), 2001227 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7098485</ArticleId><ArticleId IdType="pubmed">32217650</ArticleId></ArticleIdList></Reference><Reference><Citation>Field, T. S. et al. Risk factors for adverse drug events among nursing home residents. Arch. Intern. Med.161(13), 1629–1634 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11434795</ArticleId></ArticleIdList></Reference><Reference><Citation>Onder, G. et al. Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J. Am. Geriatr. Soc.50(12), 1962–1968 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12473007</ArticleId></ArticleIdList></Reference><Reference><Citation>Klarin, I., Wimo, A. &amp; Fastbom, J. The association of inappropriate drug use with hospitalisation and mortality: A population-based study of the very old. Drugs Aging22(1), 69–82 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15663350</ArticleId></ArticleIdList></Reference><Reference><Citation>Fialová, D. et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA293(11), 1348–1358 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15769968</ArticleId></ArticleIdList></Reference><Reference><Citation>Cvancara, D. J. et al. Postmarketing reporting of paxlovid-related dysgeusia: A real-world pharmacovigilance study. Otolaryngol. Head Neck Surg.169(1), 55–61 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36821807</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajiah, K., Sivarasa, S. &amp; Maharajan, M. K. Impact of pharmacists’ interventions and patients’ decision on health outcomes in terms of medication adherence and quality use of medicines among patients attending community pharmacies: A systematic review. Int. J. Environ. Res. Public Health18(9), 4392 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8122322</ArticleId><ArticleId IdType="pubmed">33918990</ArticleId></ArticleIdList></Reference><Reference><Citation>Haynes, R. B. et al. Interventions for enhancing medication adherence. Cochrane Database Syst. Rev.2, Cd000011 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18425859</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald, E. G. &amp; Lee, T. C. Nirmatrelvir–ritonavir for COVID-19. CMAJ194(6), E218 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8900806</ArticleId><ArticleId IdType="pubmed">35115376</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross, S. B. et al. COVID-SAFER: Deprescribing guidance for nirmatrelvir–ritonavir drug interactions in older adults. medRxiv10.1101/2022.03.01.22271254.abstract (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>